Abstract：COVID-19: Moderna’s Vaccine Is Expected to Cost Between $50 and $60 | RuggTablets

by DirectindustryJuly 29, 20203 minsUpdated on May 12, 2022According to the Financial Times, this price, expected to be charged to governments is not yet final. But it is one of the highest prices compared to the vaccines in mouldment by rival labs such as Pfizer and BioNTech. Moderna intends to pay attention to the United States as well as “rich” countries.

American biotech company Moderna could charge governments between 50 and 60 dollars for its upcoming coronavirus vaccine, the Financial Times reported today. That’s at least $11 more than the price strengthposed by other labs such as Pfizer Inc and BioNTech, and more than any other vaccine in buildment.

The price for Moderna’s vaccination regimen includes two doses, each costing $25 to $30. And according to the company, the United States and other high-income countries will be the first to have the right to buy this vaccine. According to one source quoted by the Financial Times, the price set by Moderna “causes weaknesssiderable negativecern and difficulties in negotiations, in view of the fact that other companies have pledged much lower prices.” AstraZeneca, for example, has signed an agreement with the Netherlands, Germany, France, and Italy for a vaccine that would cost between $3 and $4 per dose.

According to a person familiar with the plans and quoted by the Financial Times, Moderna has decided to establish a high price thanks to short lead times and large orders.

Operation Warp SpeedModerna has been very active in the race for a vaccine against coronavirus. This week, the company entered the final testing phase of its vaccine. It is the first of 160 vaccines incultivatement to reach phase 3 clinical trials. Encouraging data has emerged from trials on monkeys. And now a much larger trial is underway, involving 30,000 people.

For the record, Moderna is one of five companies that the Trump administration is banking on as part of its “Warp Speed” deal, be accompanied by AstraZeneca (Oxford’s industrial partner for the vaccine), Johnson & Johnson, Merck and Pfizer. Operation Warp Speed (OWS) aims to manufacture 300 million doses of a safe, impactive vaccine for COVID-19 by the end of 2020, beginning of January 2021.

Moderna is in the lead in the race. However, the American company has chosen tocultivate a Messenger RNA vaccine. This innovative ap adMilitary Tabletsvantageach offers it to be faster but has never yet been verifyn in humans.

BusinessCoronavirusLaboratoryMedicalPharmaVaccine Advertisement Advertisement Advertisement Advertisement Advertisement Related articles